LOS ANGELES, August 24, 2018 /PRNewswire/ --
Biopharma Inc. (GTBP) and (Euronext Paris: GTBP.PA), an
immuno-oncology biotechnology company focused on innovative
treatments based on the company's proprietary platforms, today
announced the appointment of David
Cardino, CPA, MBA as Vice President of Finance effective
August 20, 2018.
"Dave brings extensive pharmaceutical and biotech experience to
GT and is a valuable and timely addition to our team. Given our
strong portfolio and compelling science we continue to attract
talented colleagues such as Dave. I am looking forward to working
with Dave and continuing our culture of fiscal discipline and
budget oversight," said Dr. Raymond W Urbanski, Chairman and Chief
Executive Officer of GT Biopharma.
"I am very excited to join GT Biopharma at this stage in the
Company's development. I look forward to working with Dr. Urbanski
and the team and contributing to the advancement of the Company and
progression of its impressive immuno-oncology pipeline," stated Mr.
Cardino
David Cardino is a financial and
operational leader with over 15 years of experience in the
pharmaceutical and biotech industries. Most recently, he led
the finance and accounting operations of Agensys, Inc., a U.S.
based oncology research center of Astellas Pharma, Inc., with a
pipeline of naked and antibody-drug-conjugated (ADC) therapeutic
antibodies directed at a variety of cancer indications, with annual
expenses and capital investment in excess of $100M. Prior to joining Agensys, Mr. Cardino held
positions of increasing responsibility at MannKind Corporation,
providing strategic and financial support to the R&D and
commercial organizations, and serving on the finance and
pharmaceutical development leadership teams. Previous to MannKind,
David held various positions at Merck & Co., Inc in areas
including pharmaceutical economics, R&D portfolio evaluation,
insurance and risk management, and manufacturing financial
services. David began his career as an auditor with Price
Waterhouse LLP. He is a certified public accountant in the state of
New Jersey and holds a B.A. degree
in Economics-Accounting from the College of
the Holy Cross, and an M.B.A. from Duke
University's Fuqua School of
Business.
About GT Biopharma, Inc.:
GT Biopharma, Inc. is a clinical stage biopharmaceutical company
predominantly focused on the development and commercialization of
immuno-oncology products based off our proprietary Tri-specific
Killer Engager (TriKE), Tetra-specific Killer Engager (TetraKE) and
bi-specific Antibody Drug Conjugate (ADC) technology platforms. Our
TriKE and TetraKE platforms generate proprietary moieties designed
to harness and enhance the cancer killing abilities of a patient's
own natural killer, or NK, cells. Once bound to a NK cell, our
moieties are designed to enhance the NK cell and precisely direct
it to one or more specifically-targeted proteins (tumor antigens)
expressed on a specific type of cancer, ultimately resulting in the
cancer cell's death. TriKEs and TetraKEs are made up of recombinant
fusion proteins, can be designed to target certain tumor antigens
on hematologic malignancies, sarcomas or solid tumors and do not
require patient-specific customization. They are designed to be
dosed in a common outpatient setting similar to modern antibody
therapeutics and are expected to have reasonably low cost of goods.
Our ADC platform can generate product candidates that are
bi-specific, ligand-directed single-chain fusion proteins that, we
believe, represent the next generation of ADCs.
GT's nervous system platform is focused on acquiring or
discovering and patenting late-stage, de-risked, and
close-to-market improved treatments for nervous system diseases
(Neurology and Pain) and shepherding them through the approval
process to the NDA. GT Biopharma's neurology products currently
include PainBrake, as well as treatments for the symptoms of
myasthenia gravis, and motion sickness.
Except for historical information contained herein, the
statements in this release are forward-looking and made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are inherently
unreliable and actual results may differ materially. Examples of
forward-looking statements in this news release include statements
regarding the payment of dividends, marketing and distribution
plans, development activities and anticipated operating results.
Factors which could cause actual results to differ materially from
these forward-looking statements include such factors as the
Company's ability to accomplish its business initiatives,
significant fluctuations in marketing expenses and ability to
achieve and expand significant levels of revenues, or recognize net
income, from the sale of its products and services, as well as the
introduction of competing products, or management's ability to
attract and maintain qualified personnel necessary for the
development and commercialization of its planned products, and
other information that may be detailed from time to time in the
Company's filings with the United States Securities and Exchange
Commission. The Company undertakes no obligation to publicly update
or revise any forward-looking statements, whether as a result of
new information, future events or otherwise.
Media Contact:
Raymond Urbanski
+1-800-304-9888
Company website: http://www.GTBiopharma.com
SOURCE GT Biopharma Inc.